X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ETX2514 or SUL-DUR is a combination of sulbactam, an IV β-lactam antibiotic, and durlobactam, a rationally designed broad-spectrum IV β-lactamase inhibitor, being developed for the treatment of infections due to Acinetobacter aumanniicalcoaceticus complex.
Lead Product(s): Sulbactam,Durlobactam
Therapeutic Area: Infections and Infectious Diseases Product Name: ETX2514
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Innoviva
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2023
Details:
Sulbactam-Durlobactam (SUL-DUR) is an IV, investigational drug that is combination of sulbactam, an IV β-lactam antibiotic, and durlobactam, novel broad-spectrum IV BLI, developed for treatment of infections caused by ABC complex, including carbapenem-resistant strains.
Lead Product(s): Sulbactam,Durlobactam,Imipenem
Therapeutic Area: Infections and Infectious Diseases Product Name: ETX2514sul
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2022
Details:
Sulbactam (SUL-DUR) is a β-lactam antibiotic with activity against Acinetobacter baumannii; however, β-lactamase-mediated resistance to sulbactam is now widespread rendering it generally ineffective.
Lead Product(s): Sulbactam,Durlobactam
Therapeutic Area: Infections and Infectious Diseases Product Name: SUL-DUR
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2022
Details:
Entasis brings to Innoviva an exciting portfolio that includes potentially first- and best-in-class medicines for the treatment of multidrug-resistant Gram-negative bacteria, including lead asset SUL-DUR.
Lead Product(s): Sulbactam,Durlobactam
Therapeutic Area: Infections and Infectious Diseases Product Name: SUL-DUR
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Innoviva
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition July 11, 2022
Details:
ETX0462, a novel non-β-lactam PBP inhibitor, has potent antibacterial activity against a panel of geographically diverse Gram-negative bacterial clinical isolates.
Lead Product(s): ETX0462
Therapeutic Area: Infections and Infectious Diseases Product Name: ETX0462
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2022
Details:
The primary efficacy endpoint, 28-day all-cause mortality (ACM) in carbapenem resistant Acinetobacter baumannii-calcoaceticus (CRABC) m-MITT cohort (n=125) was 19.0% (12/63) and 32.3% (20/62) for SUL-DUR versus colistin, respectively (difference -13.2% [95% CI: -30.0, 3.5]).
Lead Product(s): Sulbactam,Durlobactam
Therapeutic Area: Infections and Infectious Diseases Product Name: SUL-DUR
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2022
Details:
SUL-DUR (Sulbactam-durlobactam), is the first investigational drug to demonstrate efficacy in a 28-day all-cause mortality trial focused on carbapenem-resistant Acinetobacter, an “Urgent” threat as designated by the CDC.
Lead Product(s): Sulbactam,Durlobactam
Therapeutic Area: Infections and Infectious Diseases Product Name: SUL-DUR
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2022
Details:
Entasis’ pathogen-targeted platform has a pipeline, including SUL-DUR (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacterales infections) & ETX0462 (targeting Gram-negative infections).
Lead Product(s): Sulbactam,Durlobactam
Therapeutic Area: Infections and Infectious Diseases Product Name: SUL-DUR
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Innoviva
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 02, 2022
Details:
SUL-DUR first to achieve statistical non-inferiority in 28-day all-cause mortality in carbapenem-resistant Acinetobacter (CRAB) patients demonstrated statistical non-inferiority versus colistin.
Lead Product(s): Sulbactam,Durlobactam
Therapeutic Area: Infections and Infectious Diseases Product Name: SUL-DUR
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2021
Details:
ETX0462 is novel, first-in-class, diazabicyclooctane with antimicrobial activity against multidrug-resistant Gram-negative and biothreat pathogens including, P. aeruginosa, K. pneumoniae, S. maltophilia, E. coli, B. anthracis, Y. pestis, F. tularensis and Burkholderia.
Lead Product(s): ETX0462
Therapeutic Area: Infections and Infectious Diseases Product Name: ETX0462
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
